<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-Senate" dms-id="A1" public-private="public">
	<metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>114 S1878 IS: Advancing Hope Act of 2015</dc:title>
<dc:publisher>U.S. Senate</dc:publisher>
<dc:date>2015-07-28</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>114th CONGRESS</congress><session>1st Session</session>
		<legis-num>S. 1878</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20150728">July 28, 2015</action-date>
			<action-desc><sponsor name-id="S309">Mr. Casey</sponsor> (for himself and <cosponsor name-id="S305">Mr. Isakson</cosponsor>) introduced the following bill; which was read twice and referred to the <committee-name committee-id="SSHR00">Committee on Health, Education, Labor, and Pensions</committee-name></action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To extend the pediatric priority review voucher program.</official-title>
	</form>
	<legis-body>
		<section id="S1" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Advancing Hope Act of 2015</short-title></quote>.</text>
 </section><section id="H2CFA4588C23F465298310C110D905BF0"><enum>2.</enum><header>Reauthorization of program for priority review To encourage treatments for rare pediatric diseases</header><text display-inline="no-display-inline">Section 529 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360ff">21 U.S.C. 360ff</external-xref>) is amended—</text> <paragraph id="HCFE3C1205292422BBF70078BB6CD77F7"><enum>(1)</enum><text>in subsection (a)—</text>
 <subparagraph id="H88EF544487D44F319A52FC0FFBB867B1"><enum>(A)</enum><text>by amending paragraph (3) to read as follows:</text> <quoted-block display-inline="no-display-inline" id="H3A2D2BEA948248DB9BC4D18F8F043A86" style="OLC"> <paragraph id="H24C57B52D45742B3BEA806822C81F04C"><enum>(3)</enum><header>Rare pediatric disease</header><text display-inline="yes-display-inline">The term <term>rare pediatric disease</term> means any of the following:</text>
 <subparagraph id="H0D212EB19C104CBFA2D3BC8BCA968045"><enum>(A)</enum><text>A disease that meets each of the following criteria:</text> <clause id="HACBA42B933DC4D85AF8E459471DD306F"><enum>(i)</enum><text>The disease primarily affects individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents.</text>
 </clause><clause id="H833937090A594F74B07F743588A93AE1"><enum>(ii)</enum><text>The disease is a rare disease or condition, within the meaning of section 526.</text> </clause></subparagraph><subparagraph id="H266C3CFA0EE14D6F9D94B32C230BB1EA"><enum>(B)</enum><text>Any form of sickle cell disease.</text>
 </subparagraph><subparagraph id="idA7506F36002D4AEDAF8EEC6AEFD211C0"><enum>(C)</enum><text>Any pediatric cancers.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block> </subparagraph><subparagraph id="H58F87CD33F19497BB7203842E97FFCD8"><enum>(B)</enum><text>in paragraph (4)—</text>
 <clause id="H102DF4FE1C0E49C38D71B0F6AFCDD45C"><enum>(i)</enum><text>in subparagraph (E), by striking <quote>and</quote> at the end;</text> </clause><clause id="H76EAA181A57A45668ADC45A62B67C809"><enum>(ii)</enum><text>in subparagraph (F), by striking the period at the end and inserting <quote>; and</quote>; and</text>
 </clause><clause id="H4779EDE79D1D4F96AFB66355A77FEE3F"><enum>(iii)</enum><text>by adding at the end the following:</text> <quoted-block display-inline="no-display-inline" id="H9639375A41664CCCA483E38FE5A6AEB8" style="OLC"> <subparagraph id="H5A62205E8A1442FBB8E649B861D892A1"><enum>(G)</enum><text display-inline="yes-display-inline">is for a drug or biological product for which a priority review voucher has not been issued under section 524 (relating to tropical disease products).</text></subparagraph><after-quoted-block>; </after-quoted-block></quoted-block>
 </clause></subparagraph></paragraph><paragraph id="HA028EAB934644866851E576F8C8BF8CB"><enum>(2)</enum><text>in subsection (b), by striking paragraph (5); and</text> </paragraph><paragraph id="id737632D0BD47463C9FD2BDF14D41B65B"><enum>(3)</enum><text>in subsection (d)(2), in the second sentence, by striking the period and inserting <quote>, but the sponsor of a drug that intends to request a priority review voucher under this section shall notify the Secretary of such intent upon submission of an application under section 505 or section 351 of the Public Health Service Act that is the basis of such request.</quote>.</text></paragraph></section></legis-body>
</bill>


